Pfizer says its vaccine is safe & effective in 5-11 year-olds: 5 things to know

1. The data comes from a phase 2/3 study that included 2,268 participants ages 5-11.
2. The trial participants received two 10-microgram doses of Pfizer’s COVID-19 vaccine, administered 21 days apart. For people ages 12 and older, Pfizer uses a 30-microgram dose.
3. Pfizer said the trial demonstrated a “favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age.” The findings have not been peer reviewed or published in a scientific journal.
4. Pfizer said it will share this data with the FDA and other regulators as soon as possible.
5. Of the drugmakers with a COVID-19 vaccine in use in the U.S., Pfizer is the first one to produce results from a trial testing its vaccine in children ages 5 to 11.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.